Celldex Therapeutics Inc., of Hampton, N.J., completed patient enrollment in its phase IIb METRIC trial testing glembatumumab vedotin, an antibody-drug conjugate that targets gpNMB, compared to Xeloda (capecitabine, Roche AG) in 327 patients with metastatic triple negative breast cancer that overexpress gpNMB.